Tri Locum Partners LP
Filing Date
Global Rank
#1,884
/ 8,232
▲ 32
Top Industry
Biotechnology
42.4%
3Y Alpha vs SPY
-0.4%
Period ended 2 months ago
Filed May 18, 2026 · 27d
22 quarters · since Dec 2020
Clone Performance
Jun 2023–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+74.7%
SPY
+76.3%
Annualised alpha
-0.4%
Max drawdown
−21.4%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
17 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
14.2%
−2.0 pts
Top 5
49.6%
−0.8 pts
Top 10
81.6%
+1.4 pts
HHI
789
Diversified−29
Portfolio Trend
22 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $712,549,404 |
Last Quarter's Activity
Export CSVTrimmed
Positions the filer reduced
8 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. /DE/ | −476,860 | 145,543 | $12,213,968 | |
| TEVA | Teva Pharmaceutical Industries Ltd | −414,857 | 1,021,008 | $30,752,760 | |
| JNJ | Johnson & Johnson | −188,640 | 414,503 | $101,321,113 | |
| AXSM | Axsome Therapeutics, Inc. | −139,511 | 62,116 | $10,498,846 | |
| UTHR | UNITED THERAPEUTICS Corp | −50,551 | 70,370 | $41,728,002 | |
| ASND | Ascendis Pharma A/S | −9,683 | 255,332 | $58,402,088 | |
| ARGX | Argenx SE | −6,018 | 31,635 | $23,101,458 | |
| LLY | ELI LILLY & Co | −1,489 | 61,795 | $56,837,187 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
6 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| ISRG | Intuitive Surgical Inc | 153,250 | $70,646,717 | |
| TMO | Thermo Fisher Scientific Inc. | 132,413 | $65,084,961 | |
| VRTX | Vertex Pharmaceuticals Inc / Ma | 129,314 | $57,743,873 | |
| JAZZ | Jazz Pharmaceuticals plc | 158,663 | $29,995,240 | |
| TARS | Tarsus Pharmaceuticals, Inc. | 252,588 | $17,719,048 | |
| DFTX | Definium Therapeutics, Inc. | 369,588 | $6,985,213 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
4 positions
17 positions ·
$712,549,404 total
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| JNJ |
Johnson & Johnson
Healthcare
|
Reduced | 414,503 | $101,321,113 | 14.22% | |
| ISRG |
Intuitive Surgical Inc
Healthcare
|
NEW | 153,250 | $70,646,717 | 9.91% | |
| TMO |
Thermo Fisher Scientific Inc.
Healthcare
|
NEW | 132,413 | $65,084,961 | 9.13% | |
| ASND |
Ascendis Pharma A/S
Healthcare
|
Reduced | 255,332 | $58,402,088 | 8.20% | |
| VRTX |
Vertex Pharmaceuticals Inc / Ma
Healthcare
|
NEW | 129,314 | $57,743,873 | 8.10% | |
| LLY |
ELI LILLY & Co
Healthcare
|
Reduced | 61,795 | $56,837,187 | 7.98% | |
| MDGL |
Madrigal Pharmaceuticals, Inc.
Healthcare
|
Added | 103,288 | $54,068,169 | 7.59% | |
| DXCM |
Dexcom Inc
Healthcare
|
Added | 698,158 | $43,844,322 | 6.15% | |
| UTHR |
UNITED THERAPEUTICS Corp
Healthcare
|
Reduced | 70,370 | $41,728,002 | 5.86% | |
| NUVL |
Nuvalent, Inc.
Healthcare
|
Added | 308,506 | $31,606,439 | 4.44% | |
| TEVA |
Teva Pharmaceutical Industries Ltd
Healthcare
|
Reduced | 1,021,008 | $30,752,760 | 4.32% | |
| JAZZ |
Jazz Pharmaceuticals plc
Healthcare
|
NEW | 158,663 | $29,995,240 | 4.21% | |
| ARGX |
Argenx SE
Healthcare
|
Reduced | 31,635 | $23,101,458 | 3.24% | |
| TARS |
Tarsus Pharmaceuticals, Inc.
Healthcare
|
NEW | 252,588 | $17,719,048 | 2.49% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
Reduced | 145,543 | $12,213,968 | 1.71% | |
| AXSM |
Axsome Therapeutics, Inc.
Healthcare
|
Reduced | 62,116 | $10,498,846 | 1.47% | |
| DFTX |
Definium Therapeutics, Inc.
Healthcare
|
NEW | 369,588 | $6,985,213 | 0.98% |